This article previews some formulation topics discussed in the Pharma Fundamentals series, which aims to enhance learning for professionals in pharmaceutical drug development and manufacturing. It is ...
LNPs continue to dominate the spotlight in biopharma with three landmark acquisitions in the past six months, AbbVie/Capstan Therapeutics, Eli Lilly and Co/Verve Therapeutics and Bristol Myers ...
In the last 10 years, there has been significant development in computer simulation of pharmaceutical materials, processes and product performance. Gradually, more mechanistically based models are ...
Formulation scientists are behind the conversion of active pharmaceutical ingredients (API) into stable, bioavailable, and commercially viable dosage forms, rarely a simple process. Image Credit: ...
AI/ML technologies are revolutionizing pharmaceutical formulation by optimizing excipient selection and predicting stability, reducing time and resources needed for development. Poor solubility of ...
Stability is a critical factor in drug formulation, with implications for product quality, lifecycle management, and ...
Patients with some cancers, autoimmune diseases, and metabolic disorders often endure time-consuming intravenous (IV) infusions to receive the best protein-based treatments available. Because these ...
The funding round was led by Spero Ventures with participation from MBX Capital, Shimadzu Future Innovation Fund managed by Global Brain Corporation, Eli Lilly & Company, SignalFire, Ford Street ...
Firms will offer integrated solutions for multiparticulate oral controlled-release products. Drug formulation and delivery specialists Bend Research and Catalent Pharma Solutions inked an agreement to ...
Hosted on MSN
India raising the bar on drug formulation challenges
India has long been hailed as the pharmacy of the world, thanks to its robust generics sector and formidable manufacturing capabilities. Today, the Indian pharmaceutical industry is poised to leverage ...
Xiaoping Wu of Wanhuida Intellectual Property explains how the CNIPA’s recent invalidation of a sustained-release patent illustrates key considerations in assessing inventive step for pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results